536 results on '"Reed, Eddie"'
Search Results
2. DNA Repair: ERCC1, Nucleotide Excision Repair, and Platinum Resistance
3. Validation of a venous thromboembolism risk assessment model in gynecologic oncology
4. CHK2 and ERCC1 in the DNA Adduct Repair Pathway that Mediates Acquired Cisplatin Resistance
5. Thalidomide : A Prodrug That Inhibits Angiogenesis
6. Nucleotide excision repair and anti-cancer chemotherapy
7. Phase I Trials with Ormaplatin (Tetraplatin)
8. Gene Specific Damage and Repair of Platinum Adducts and Crosslinks
9. Peripheral Blood Leukocytes as a Surrogate Marker for Cisplatin Drug Resistance: Studies of Adduct Levels and the Repair Gene ERCC1
10. Measurement of DNA Adducts by Immunoassays
11. Platinum-DNA Adducts in Leukocyte DNA Correlate with Disease Response in Ovarian Cancer Patients Receiving Platinum-Based Chemotherapy
12. Biological Impact of Small Air Ions
13. Cisplatin-DNA Damage and Repair in Peripheral Blood Leukocytes in Vivo and in Vitro
14. Platinum Drug-DNA Interactions in Human Tissues Measured by Cisplatin-DNA Enzyme-Linked Immunosorbent Assay and Atomic Absorbance Spectroscopy
15. Polyclonal Antibodies to Quantitate Cis-Diamminedichloroplatinum(II)-DNA Adducts in Cancer Patients and Animal Models
16. Pharmacodynamic stimulation of thrombogenesis by angiotensin (1–7) in recurrent ovarian cancer patients receiving gemcitabine and platinum-based chemotherapy
17. Enhancement of cisplatin-induced apoptosis by β-elemene in resistant human ovarian cancer cells
18. Sensitization of lung cancer cells to cisplatin by β-elemene is mediated through blockade of cell cycle progression: antitumor efficacies of β-elemene and its synthetic analogs
19. CD44+/CD24− ovarian cancer cells demonstrate cancer stem cell properties and correlate to survival
20. Colorectal Cancer Screening Practices in Alabama: A Survey of Primary Care Physicians
21. DNA Repair: ERCC1, Nucleotide Excision Repair, and Platinum Resistance
22. Duration of Cisplatin Excretion in Breast Milk
23. Vascular endothelium summary statement III: Cancer prevention and control
24. Vascular endothelium summary statement VI: Research directions for the 21st century
25. Gleason score and pretreatment prostate-specific antigen in survival among patients with stage D2 prostate cancer
26. Phase II trial of carboplatin and infusional cyclosporine in platinum-resistant recurrent ovarian cancer
27. Suramin's Development: What Did we Learn?
28. Adenoviral delivery of A-FOS, an AP-1 dominant negative, selectively inhibits drug resistance in two human cancer cell lines
29. An ERCC1 splicing variant involving the 5′-UTR of the mRNA may have a transcriptional modulatory function
30. Myb overexpression overrides androgen depletion–induced cell cycle arrest and apoptosis in prostate cancer cells, and confers aggressive malignant traits: potential role in castration resistance
31. Enhancing Response Rates in Physician Surveys: The Limited Utility of Electronic Options
32. Pharmacokinetics and Relative Bioavailability of Carboxyamido-Triazole with Respect to Food and Time of Administration: Use of a Single Model for Simultaneous Determination of Changing Parameters
33. Evaluation of Cisplatin in Combination with β-Elemene as a Regimen for Prostate Cancer Chemotherapy
34. Antineoplastic effect of β-elemene on prostate cancer cells and other types of solid tumour cells
35. Ten-year follow-up of a phase 2 study of dose-intense paclitaxel with cisplatin and cyclophosphamide as initial therapy for poor-prognosis, advanced-stage epithelial ovarian cancer
36. Synergistic effect and possible mechanisms of tumor necrosis factor and cisplatin cytotoxicity under moderate hyperthermia against gastric cancer cells
37. A phase I/II study of continuous infusion suramin in patients with hormone-refractory prostate cancer : toxicity and response
38. Irofulven induces replication-dependent CHK2 activation related to p53 status
39. Genomic copy number changes of DNA repair genes ERCC1 and ERCC2 in human gliomas
40. A Preliminary Risk-Benefit Assessment of Paclitaxel
41. Writing a Clinical Protocol
42. ERCC1 Measurements in Clinical Oncology
43. Foreword: Promoting the Use of Registry-Based National Cancer Surveillance Data for Colorectal Cancer Prevention and Control
44. MZF1 possesses a repressively regulatory function in ERCC1 expression
45. Steady-state plasma concentrations and effects of taxol for a 250 mg/m2 dose in combination with granulocyte-colony stimulating factor in patients with ovarian cancer
46. Thalidomide
47. Phase II Trial of Carboxyamidotriazole in Patients With Relapsed Epithelial Ovarian Cancer
48. Factors Involved in the Pharmacokinetics of COL-3, a Matrix Metalloproteinase Inhibitor, in Patients with Refractory Metastatic Cancer: Clinical and Experimental Studies
49. A Phase I/II Study of High-Dose Tamoxifen in Combination with Vinblastine in Patients with Androgen-Independent Prostate Cancer
50. Drug-Induced Lupus Associated With COL-3: Report of 3 Cases
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.